Quarterly ResultAug 4, 2026, 04:04 PM
Syndax Q2 2026 Revenue Jumps 92% to $72.8M; Revuforj Sales Up 91%
AI Summary
Syndax Pharmaceuticals reported strong financial results for the second quarter of 2026, with total revenue increasing 92% year-over-year to $72.8 million. This growth was driven by significant increases in net revenue for both Revuforj ($54.7 million, up 91%) and Niktimvo ($60.3 million, up 67%), with Niktimvo contributing $18.1 million in collaboration revenue. The company also provided positive updates on its expanded pipeline, including two new assets and anticipated topline data from key Phase 2 trials in Q4 2026, and expects to reach profitability with its current financial position and projected revenues.
Key Highlights
- Total revenue for Q2 2026 was $72.8 million, a 92% increase year-over-year.
- Revuforj net revenue reached $54.7 million, up 91% year-over-year.
- Niktimvo net revenue was $60.3 million, a 67% increase year-over-year, contributing $18.1 million in collaboration revenue to Syndax.
- Cash, cash equivalents, and investments totaled $575.1 million as of June 30, 2026.
- Net loss attributable to common stockholders was $49.4 million, or $0.55 per share.
- Topline data from Phase 2 trials of axatilimab in IPF and frontline cGVHD are expected in Q4 2026.
- IND submission for SNDX-4321 (EGFR inhibitor) expected by end of 2026.
- IND submission for SNDX-62122 (next-gen menin inhibitor) expected in 2027.
Price Impact
More from SNDX